James E Mcfarland

US Patent:

55062350, Apr 9, 1996

Filed:

Jan 2, 1994

Appl. No.:

8/190113

Inventors:

Mikel P. Moyer - Clinton CT
James W. McFarland - Lyme CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 3144
A61K 31535
C07D47104
C07D41314

US Classification:

514293

Abstract:

This invention relates to compounds of the formula ##STR1## wherein R. sup. 1, R. sup. 2, R. sup. 3, R. sup. 4, R. sup. 5, R. sup. 6 and R. sup. 7 are as defined hereinbelow that exhibit activity as immunostimulants.

US Patent:

39975274, Dec 14, 1976

Filed:

Feb 17, 1976

Appl. No.:

5/658384

Inventors:

James W. McFarland - Lyme CT
Colin Thomson - Groton CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D49958

US Classification:

2602391

Abstract:

6-(Aminomethyl substituted phenyl- and thienylacetamido)-penicillanic acid and esters, and synthetic methods for the preparation thereof.

US Patent:

40091600, Feb 22, 1977

Filed:

Feb 17, 1976

Appl. No.:

5/658489

Inventors:

James W. McFarland - Lyme CT
Colin Thomson - Groton CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D49958

US Classification:

2602391

Abstract:

6-(Aminomethyl substituted phenyl- and thienylacetamido)penicillanic acid and esters, and synthetic methods for the preparation thereof.

US Patent:

39489116, Apr 6, 1976

Filed:

Nov 19, 1974

Appl. No.:

5/525183

Inventors:

James W. McFarland - Lyme CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D24144

US Classification:

260250QN

Abstract:

Compounds of the formula ##SPC1## Wherein X is a 6- or 7-position substituent selected from the group consisting of formyl, acetyl, hydroxymethyl, 1-hydroxyethyl and ##EQU1## wherein Y is selected from the group consisting of hydrogen and methyl; R. sub. 1 is hydrogen or methyl; R. sub. 2, when taken separately, is hydrogen or alkyl having 1 to 4 carbon atoms; R. sub. 3, when taken separately, is hydrogen, alkyl having 1 to 4 carbon atoms, --(CH. sub. 2). sub. n OH, --(CH. sub. 2). sub. n OCH. sub. 3, --(CH. sub. 2). sub. n NH. sub. 2, ##EQU2## or ##EQU3## wherein n is 2 or 3 and R. sub. 2 and R. sub. 3, when taken together with the nitrogen atom to which they are attached, form a member selected from the group consisting of pyrrolo, pyrrolidino, piperidino, morpholino, thiomorpholino, piperazino, N-(lower alkyl)piperazino, N-hydroxy(lower alkyl)piperazino, N-(lower alkanoyl)piperazino and N-carbo(lower alkoxy)piperazino and the pharmaceutically acceptable acid addition salts of those compounds wherein R. sub. 2 has an. omega. -aminoalkyl moiety; methods for their preparation; and their use as antibacterial agents and as agents for promoting growth and improving feed efficiency of animals.

US Patent:

39667103, Jun 29, 1976

Filed:

Nov 12, 1974

Appl. No.:

5/523024

Inventors:

James W. McFarland - Lyme CT
Colin Thomson - Groton CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D49968

US Classification:

2602391

Abstract:

6-(Aminomethyl substituted phenyl- and thienylacetamido)-penicillanic acid and esters, and synthetic methods for the preparation thereof.

US Patent:

39311740, Jan 6, 1976

Filed:

Jan 23, 1974

Appl. No.:

5/435874

Inventors:

James W. McFarland - Lyme CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D24144

US Classification:

260250Q

Abstract:

Novel quinoxaline-1,4-dioxides of the formula ##SPC1## Wherein R is hydrogen or methyl; Y is lower alkyl; and n is 0, 1, or 2; Methods for their preparation; and their use as antibacterial agents and agents for promoting growth and improving feed efficiency of animals. Additionally, those compounds wherein n is 0 or 1 serve as intermediates for preparation of compounds wherein n is 1 or 2.

US Patent:

20220340976, Oct 27, 2022

Filed:

Sep 1, 2020

Appl. No.:

17/639532

Inventors:

- Cambridge MA, US
- Boston MA, US
Aviad Tsherniak - Cambridge MA, US
James McFarland - Cambridge MA, US
Brenton Paolella - Cambridge MA, US

Assignee:

THE BROAD INSTITUTE, INC. - Cambridge MA
DANA-FARBER CANCER INSTITUTE, INC. - Boston MA

International Classification:

C12Q 1/6886
G06N 20/00
G06N 3/08

Abstract:

The present disclosure relates to compositions and methods for rapid prediction, based upon early single cell transcriptomic assessment of a biopsied sample obtained from a subject, of whether a subject will be responsive to a drug.